372 related articles for article (PubMed ID: 17370319)
21. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
Fischer MA; Avorn J
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
[TBL] [Abstract][Full Text] [Related]
22. Increased costs and rates of use in the California workers' compensation system as a result of self-referral by physicians.
Swedlow A; Johnson G; Smithline N; Milstein A
N Engl J Med; 1992 Nov; 327(21):1502-6. PubMed ID: 1406882
[TBL] [Abstract][Full Text] [Related]
23. Workers' compensation: a historical review and description of a legal and social insurance system.
Kiselica D; Sibson B; Green-McKenzie J
Clin Occup Environ Med; 2004 May; 4(2):v, 237-47. PubMed ID: 15182746
[TBL] [Abstract][Full Text] [Related]
24. Workers' compensation payment issues.
Weber RD
J Mich Dent Assoc; 2002 May; 84(5):20. PubMed ID: 12046106
[No Abstract] [Full Text] [Related]
25. The lowdown on those plummeting workers' comp costs.
Leavenworth G
Bus Health; 1995 Apr; 13(4):37-8, 40-1. PubMed ID: 10152740
[No Abstract] [Full Text] [Related]
26. Opioid prescriptions in canadian workers' compensation claimants: prescription trends and associations between early prescription and future recovery.
Gross DP; Stephens B; Bhambhani Y; Haykowsky M; Bostick GP; Rashiq S
Spine (Phila Pa 1976); 2009 Mar; 34(5):525-31. PubMed ID: 19247173
[TBL] [Abstract][Full Text] [Related]
27. A review of prescription pricing and a call for equitable payment.
Grapes ZT; Brown TR
Hospitals; 1976 Jul; 50(13):91-2, 96, 98. PubMed ID: 1278895
[TBL] [Abstract][Full Text] [Related]
28. Obesity and workers' compensation: results from the Duke Health and Safety Surveillance System.
Ostbye T; Dement JM; Krause KM
Arch Intern Med; 2007 Apr; 167(8):766-73. PubMed ID: 17452538
[TBL] [Abstract][Full Text] [Related]
29. Knocking at the wrong door: insured workers' inadequate psychiatric care and workers' compensation claims.
Hamm RM; Reiss DM; Paul RK; Bursztajn HJ
Int J Law Psychiatry; 2007; 30(4-5):416-26. PubMed ID: 17658603
[TBL] [Abstract][Full Text] [Related]
30. Workers' compensation costs: still a challenge.
Green-McKenzie J
Clin Occup Environ Med; 2004 May; 4(2):ix, 395-8. PubMed ID: 15182757
[TBL] [Abstract][Full Text] [Related]
31. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
Andersson K; Bergström G; Petzold MG; Carlsten A
Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
[TBL] [Abstract][Full Text] [Related]
32. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
McManus P; Birkett DJ; Dudley J; Stevens A
Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
[TBL] [Abstract][Full Text] [Related]
33. Economic aspects of the new Spanish laws on pharmaceutical preparations.
Antoñanzas F; Oliva J; Pinillos M; Juàrez C
Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
[TBL] [Abstract][Full Text] [Related]
34. The economic burden of gout on an employed population.
Brook RA; Kleinman NL; Patel PA; Melkonian AK; Brizee TJ; Smeeding JE; Joseph-Ridge N
Curr Med Res Opin; 2006 Jul; 22(7):1381-9. PubMed ID: 16834837
[TBL] [Abstract][Full Text] [Related]
35. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
[No Abstract] [Full Text] [Related]
36. The price of pharmaceuticals given managed care health insurance membership.
Brotman BA
Pharm Pract Manag Q; 2000 Jul; 20(2):16-9. PubMed ID: 11184047
[TBL] [Abstract][Full Text] [Related]
37. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
38. Out-of-pocket costs to users: medicine options for hypertension.
Arredondo A
Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
[No Abstract] [Full Text] [Related]
39. Increased costs and rates of use in the California workers' compensation system as a result of a self-referral by physicians.
Doane WW
N Engl J Med; 1993 Apr; 328(17):1276; author reply 1277. PubMed ID: 8464444
[No Abstract] [Full Text] [Related]
40. Copayment for pharmaceutical services in a Medicaid program.
Nelson AA; Quick MR
Contemp Pharm Pract; 1980; 3(1):37-42. PubMed ID: 10297666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
